This company has been acquired
Landos Biopharma (LABP) Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LABP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Landos Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.93 |
| 52 Week High | US$22.94 |
| 52 Week Low | US$2.50 |
| Beta | 0.14 |
| 1 Month Change | 2.78% |
| 3 Month Change | 267.47% |
| 1 Year Change | 693.43% |
| 3 Year Change | -79.12% |
| 5 Year Change | n/a |
| Change since IPO | -80.89% |
Recent News & Updates
Recent updates
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
Mar 22
Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer
Sep 06Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky
Aug 19Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
May 05Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business
Nov 17We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully
May 04Shareholder Returns
| LABP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.0% | -0.6% | 3.4% |
| 1Y | 693.4% | 39.1% | 28.4% |
Return vs Industry: LABP exceeded the US Pharmaceuticals industry which returned 18.6% over the past year.
Return vs Market: LABP exceeded the US Market which returned 25.6% over the past year.
Price Volatility
| LABP volatility | |
|---|---|
| LABP Average Weekly Movement | 49.2% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: LABP's share price has been volatile over the past 3 months.
Volatility Over Time: LABP's weekly volatility has increased from 26% to 49% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 19 | Greg Oakes | landosbiopharma.com |
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company’s preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD.
Landos Biopharma, Inc. Fundamentals Summary
| LABP fundamental statistics | |
|---|---|
| Market cap | US$71.68m |
| Earnings (TTM) | -US$24.80m |
| Revenue (TTM) | n/a |
Is LABP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LABP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.80m |
| Earnings | -US$24.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LABP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/26 17:40 |
| End of Day Share Price | 2024/05/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Landos Biopharma, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |